NCT01239030

Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

230 people

33%

67%

76 womenmiddle line = equal numbers154 men

Phase: PHASE3
Paid for by: Rhodes Pharmaceuticals, L.P.
Finished: 2012-03
Health conditions: Attention Deficit Hyperactivity Disorder, ADHD
Who could join: Anyone
Ages: 6 Years – 18 Years
Average age: mean 10.8 years
Age 65+: 0%
Weight (BMI): Not reported
Pregnancy recorded: Not reported
Menopause recorded: Not reported
Results shown by sex: Not split by sex
Race: White 68.7% · Black / African American 23% · Not reported 5.2% · Asian 1.3% · American Indian / Alaska Native 0.9% · Native Hawaiian / Pacific Islander 0.9% · More than one race 0%

Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 18 Years.”
No pregnant women
Women who were pregnant could not join.
“Is pregnant or breast-feeding”
No breastfeeding moms
Women who were breastfeeding could not join.
“Is pregnant or breast-feeding”
Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“Females of child-bearing potential not pregnant and practice birth control”
No seizures
Women with epilepsy or past seizures were turned away.
“Chronic medical illnesses: seizure, hypertension, thyroid disease, cardiac, family history of sudden death, glaucoma”
No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“Current primary psychiatric diagnosis of other listed disorders”

Study titles and rules are shown in their original English.